After the decisions at the most recent crucial meeting of the responsible Fed committee, it was actually just a mere formality in the end. The US approval for BioNTechs and Pfizer’s mRNA-based COVID-19 vaccine BNT162b2 for people aged 16 and over came at record speed. It is the “largest” marketing authorization to date for the vaccine, which is already in use in Great Britain and most recently made some waves.
It fills “with great pride and joy, and the fact that Pfizer rose to the challenge of helping to develop a vaccine that has the potential to end this devastating pandemic,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer.
“Returning to Normal Life in the United States”
“We founded BioNTech with the aim of developing new technologies and drugs that harness the full potential of the immune system to fight life-threatening diseases,” said Ugur Sahin, CEO and co-founder of BioNTech. “Today we have come a big step closer to this vision. We believe that today’s emergency approval and associated distribution of our vaccine – which has shown 95% effectiveness and a well-tolerated safety profile – will help save lives and accelerate the return to normal life in the United States ” said the manager.